Hepatitis E virus infections in Europe
•The increasing number of symptomatic cases reported in Europe is linked to greater clinical awareness and the optimisation of test algorithms.•HEV genotype 3, which is zoonotic, is the most prevalent genotype in Europe.•The three major clades and subgenotypes of HEV-3 differ geographically and chan...
Gespeichert in:
Veröffentlicht in: | Journal of clinical virology 2019-11, Vol.120, p.20-26 |
---|---|
Hauptverfasser: | , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | •The increasing number of symptomatic cases reported in Europe is linked to greater clinical awareness and the optimisation of test algorithms.•HEV genotype 3, which is zoonotic, is the most prevalent genotype in Europe.•The three major clades and subgenotypes of HEV-3 differ geographically and changes in distribution over the time have been observed.•Severe liver disease caused by HEV-3 occurs in patients with underlying chronic liver disease and in immunocompromised patients.•Neurological and renal manifestations of HEV infection are increasingly recognised.
Hepatitis E virus (HEV) is the most common cause of acute viral hepatitis worldwide. The systematic use of improved tools for diagnosing and genotyping has completely changed our understanding of the epidemiology and clinical consequences of HEV infection. Most cases of HEV in Europe arise from infected animals such as pigs, wild boar, deer and rabbits. Zoonotic HEV genotypes (HEV genotypes 3–8) are mainly food-borne or transmitted by direct contact, but recent data suggest that infection can also be water-borne or even iatrogenic throught contamined blood products.
HEV-3 is the most prevalent genotype in Europe but the geographic distributions of the 3 major clades and subgenotypes (HEV-3abjkchi, HEV-3efg, and HEV-3ra) differ. Most HEV-3 infections are asymptomatic but they can result in severe acute hepatitis in patients with chronic liver disease, chronic hepatitis in immunocompromised patients, and to extra-hepatic manifestations.
Despite more frequent reports of symptomatic hepatitis E cases across Europe, systems for monitoring HEV infections vary greatly. Severe HEV-associated illnesses, hospitalizations and deaths are probably underestimated. The seroprevalence and incidence of locally acquired hepatitis E varies between and within European countries and over time. The precise origin of these variations is uncertain but may be linked to environmental factors or the degree to which HEV contaminates the human food chain. Collaborative initiatives such as the establishment of the One Health platform for HEV sequences (HEVnet database) will be very useful for a better understanding of the epidemiology of HEV in Europe and the development of effective prevention strategies. |
---|---|
ISSN: | 1386-6532 1873-5967 |
DOI: | 10.1016/j.jcv.2019.09.004 |